Event Banner

The Tata Memorial Centre claims Rs 100 tablet effectively prevents cancer recurrence

Tata Institute in Mumbai has unveiled a revolutionary advancement in cancer care. Following ten years of intensive research, they have introduced a groundbreaking tablet designed to thwart cancer recurrence and alleviate treatment side effects by an impressive 50%.


Revolutionary Tablet


Pioneered by researchers and medical experts at the Tata Institute, the newly developed tablet, dubbed 'R+Cu', incorporates pro-oxidant compounds such as resveratrol and copper. These compounds unleash oxygen radicals within the stomach, effectively targeting and neutralizing chromatin particles released by dying cancer cells. This mechanism not only prevents healthy cells from succumbing to cancerous transformation but also impedes the spread of cancer cells, a process known as 'Metastases'.


Clinical Trials and Regulatory Approval


Initial trials on rats have showcased promising outcomes in terms of side effect mitigation and cancer prevention. However, comprehensive human trials are still underway and are anticipated to span approximately five years. Regulatory clearance from the Food Safety and Standards Authority of India (FSSAI) is pending, with expectations for the tablet to hit the market by June-July.


Accessible Treatment


One of the most remarkable aspects of this breakthrough is its affordability. While conventional cancer treatments often entail exorbitant costs ranging from lakhs to crores, this tablet is projected to be priced at a mere ₹100, rendering it accessible to a broader demographic.


Dr. Rajendra Badve, a distinguished cancer surgeon at Tata Memorial Hospital, expressed optimism about the tablet's prospects, stating, "Tata doctors have dedicated nearly a decade to the development of this tablet. It's currently awaiting approval from the Food Safety and Standards Authority of India (FSSAI). TIFR scientists have submitted the necessary applications for approval. Once authorized, it will be readily available in the market by June-July. This tablet has the potential to significantly enhance cancer treatment."


"As opposed to the substantial expenses typically associated with cancer treatment, this tablet will be universally affordable at just ₹100," he emphasized.


Future Outlook


The tablet not only exhibits promise in averting cancer recurrence but also in mitigating treatment-related adverse effects. Researchers speculate its efficacy in combating pancreatic, lung, and oral cancers.


The advent of this tablet marks a monumental stride in cancer therapy, instilling hope among patients and potentially reshaping the landscape of oncological care. Its cost-effectiveness and efficacy position it as a transformative asset in the realm of oncology.

29 February 2024

Recent


Update Image

The Tata Memorial Centre claims Rs 100 tablet effectively prevents cancer recurrence

29 Feb 2024

Update Image

SPARSH Hospital signs MoU with GE HealthCare to Advance Clinical Care in India

29 Feb 2024

Update Image

Central Government Amends Surrogacy Regulations, Allowing Couples with Medical Conditions to Utilize Donor Gametes

29 Feb 2024

Update Image

Supreme Court Restricts Patanjali's Product Advertisements

29 Feb 2024

Update Image

Apollo Proton Cancer Centre Unveils India's First Integrated Organ & Disease-Specific Programme for Management of Rectal Cancer

28 Feb 2024

Update Image

Zeno Health Raises $25 Million in Series C Funding to Fuel Healthcare Expansion

28 Feb 2024

Update Image

Mother Donates Part of Liver to 12-Year-Old Son in Lifesaving Transplant

28 Feb 2024

Update Image

Cipla strengthens fight against AMR, secures approval to introduce ZEMDRI® (plazomicin) injection in India

27 Feb 2024

Update Image

Charting the Future of Healthcare: Apollo Hospitals' 11th International Health Dialogue Spotlights Health Equity, Sustainability, and AI Advancement 

27 Feb 2024

Update Image

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

27 Feb 2024

Unlock the power of Synergy

Collaborate with us